Antibiotics in critically ill patients: A systematic review of the pharmacokinetics of β-lactams.
Open accessThe DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Abstract
Introduction: Several reports have shown marked heterogeneity of antibiotic pharmacokinetics (PK) in patients admitted to ICUs, which might potentially affect outcomes. Therefore, the pharmacodynamic (PD) parameter of the efficacy of β-lactam antibiotics, that is, the time that its concentration is above the bacteria minimal inhibitory concentration (T > MIC), cannot be safely extrapolated from data derived from the PK of healthy volunteers. Methods: We performed a full review of published studies addressing the PK of intravenous β-lactam antibiotics given to infected ICU patients. Study selection comprised a comprehensive bibliographic search of the PubMed database and bibliographic references in relevant reviews from January 1966 to December 2010. We selected only English-language articles reporting studies addressing β-lactam antibiotics that had been described in at least five previously published studies. Studies of the PK of patients undergoing renal replacement therapy were excluded. Results: A total of 57 studies addressing six different β-lactam antibiotics (meropenem, imipenem, piperacillin, cefpirome, cefepime and ceftazidime) were selected. Significant PK heterogeneity was noted, with a broad, more than twofold variation both of volume of distribution and of drug clearance (Cl). The correlation of antibiotic Cl with creatinine clearance was usually reported. Consequently, in ICU patients, β-lactam antibiotic half-life and T > MIC were virtually unpredictable, especially in those patients with normal renal function. A better PD profile was usually obtained by prolonged or even continuous infusion. Tissue penetration was also found to be compromised in critically ill patients with septic shock. Conclusions: The PK of β-lactam antibiotics are heterogeneous and largely unpredictable in ICU patients. Consequently, the dosing of antibiotics should be supported by PK concepts, including data derived from studies of the PK of ICU patients and therapeutic drug monitoring.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Heterogeneity of volume of distribution in litres of β-lactam antibiotics in ICU patients. Open circles: volume of distribution in healthy volunteers [44,51,89-92]; filled squares: weighted means of volume of distribution in the studies; straight lines: ranges of the means of volume of distribution in the studies.](https://figures.cochat.ai/paper-figures/83611cc812e44433b6b33a2cd391c970/antibiotics-in-critically-ill-patients-a-systematic-review-of-the-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Beta-lactam antibiotics may be subject to changes in important pharmacokinetic parameters in the setting of sepsis and septic shock resulting in sub-therapeutic concentrations [230, 231].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [230]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Study of the Prevalence and Outcomes of Infection in Intensive Care Units
Vincent, J.-L. (2009) · JAMA · doi:10.1001/jama.2009.1754 · Cited by 3,618
Basic & Clinical Biostatistics
Dawson, B. K., & Trapp, R. G. (2004) · Cited by 699
Craig, W. A. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00065-5 · Cited by 556 · cited 1×
“Considerable evidence demonstrates that free drug time above bacteria minimal inhibitory concentration (f T > MIC) is the measure of drug exposure most closely linked to the ability of b-lactam antibiotics to kill the target bacteria [4].”
BackgroundThe epidemiology of the systemic inflammatory response
Brun-Buisson, C. (2000) · Intensive Care Medicine · doi:10.1007/s001340051121 · Cited by 534 · cited 1×
“Infection and sepsis, whether community- or hospitalacquired, are important causes of morbidity and mortality in ICU patients [1,2].”
BackgroundFridkin, S. K., Steward, C. D., Edwards, J. R., Pryor, E. R., McGowan, Jr., Archibald, L. K., Gaynes, R. P., & Tenover, F. C. (1999) · Clinical Infectious Diseases · doi:10.1086/520193 · Cited by 486
McKinnon, P. S., Paladino, J. A., & Schentag, J. J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.12.009 · Cited by 464
Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock
Taccone, F. S., Laterre, P.-F., Dugernier, T., Spapen, H., Delattre, I., Wittebole, X., De Backer, D., Layeux, B., Wallemacq, P., Vincent, J.-L., et al. (2010) · Critical Care · doi:10.1186/cc9091 · Cited by 369 · cited 2×
“…= 8 mg/L: bolus 70%, CI 100% CFR for EC: bolus 100%, CI 100% CFR for PA: bolus 40.6%, CI 100% Ceftazidime, 2 g 70% T > 4 × EUCAST breakpoint of PA 28% Taccone et al., 2010 [23] Cefepime, 2 g 70% T > 4 × EUCAST breakpoint of PA 16% Meropenem, 1 g 40% T > 4 × EUCAST breakpoint of PA…”
BackgroundInfluentialRoberts, J. A., Kirkpatrick, C. M. J., Roberts, M. S., Robertson, T. A., Dalley, A. J., & Lipman, J. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp139 · Cited by 347 · cited 13×
“…± 4.9 6.7 ± 4.2 3.7 ± 1.9 N = 6 Age 65.7 ± 11.2 years Peritonitis Descriptive Karjagin et al., 2008 [25] Meropenem 22.7 13.6 ± 1.3 NR N = 10 Age range 48 to 63 years Severe sepsis Randomized, parallel controlled Roberts et al., 2009 [24] Meropenem Meropenem 30.1 [21.7 to 53.9]e Meropenem 8 [5 to…”
BackgroundMethodInfluentialTherapeutic drug monitoring of β-lactams in critically ill patients: proof of concept
Roberts, J. A., Ulldemolins, M., Roberts, M. S., McWhinney, B., Ungerer, J., Paterson, D. L., & Lipman, J. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.06.008 · Cited by 334
Pea, F., Viale, P., & Furlanut, M. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544100-00002 · Cited by 327 · cited 1×
“Drugs that distribute essentially in the extracellular fluid (mainly hydrophilic) have low Vd, whilst drugs that have rapid cellular uptake (lipophilic) have high Vd[5,6].”
Background
Cited by
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Persistent bacterial infections and persister cells
Fisher, R. A., Gollan, B., & Helaine, S. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.42 · Cited by 1,243
Roberts, J. A., Paul, S. K., Akova, M., Bassetti, M., De Waele, J. J., Dimopoulos, G., Kaukonen, K.-M., Koulenti, D., Martin, C., Montravers, P., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu027 · Cited by 1,090
“It has been suggested that superior infection outcomes could be achieved in critically ill patients by optimization of the pharmacokinetic exposure of antibiotics [5, 6].”
BackgroundAntimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
Abdul-Aziz, M. H., Alffenaar, J.-W. C., Bassetti, M., Bracht, H., Dimopoulos, G., Marriott, D., Neely, M. N., Paiva, J.-A., Pea, F., Sjovall, F., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06050-1 · Cited by 1,081
“acyclovir, aminoglycosides, beta-lactams, daptomycin, fluconazole and glycopeptides), this can result in a significantly expanded Vd [7].”
BackgroundRoberts, J. A., Abdul-Aziz, M. H., Lipman, J., Mouton, J. W., Vinks, A. A., Felton, T. W., Hope, W. W., Farkas, A., Neely, M. N., Schentag, J. J., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70036-2 · Cited by 1,046
Guilhaumou, R., Benaboud, S., Bennis, Y., Dahyot-Fizelier, C., Dailly, E., Gandia, P., Goutelle, S., Lefeuvre, S., Mongardon, N., Roger, C., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2378-9 · Cited by 543
Too much of a good thing: a retrospective study of β-lactam concentration–toxicity relationships
Imani, S., Buscher, H., Marriott, D., Gentili, S., & Sandaradura, I. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx209 · Cited by 320
Falagas, M. E., Tansarli, G. S., Ikawa, K., & Vardakas, K. Z. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cis857 · Cited by 283
A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis
Dulhunty, J. M., Roberts, J. A., Davis, J. S., Webb, S. A. R., Bellomo, R., Gomersall, C., Shirwadkar, C., Eastwood, G. M., Myburgh, J., Paterson, D. L., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201505-0857oc · Cited by 264
Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents
Asín-Prieto, E., Rodríguez-Gascón, A., & Isla, A. (2015) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2015.02.001 · Cited by 262
Clinical implications of antibiotic pharmacokinetic principles in the critically ill
Udy, A. A., Roberts, J. A., & Lipman, J. (2013) · Intensive Care Medicine · doi:10.1007/s00134-013-3088-4 · Cited by 234
Livermore, D. M. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.12.012 · Cited by 232
Egi, M., Ogura, H., Yatabe, T., Atagi, K., Inoue, S., Iba, T., Kakihana, Y., Kawasaki, T., Kushimoto, S., Kuroda, Y., et al. (2021) · Journal of Intensive Care · doi:10.1186/s40560-021-00555-7 · Cited by 224
Kollef, M. H., Torres, A., Shorr, A. F., Martin-Loeches, I., & Micek, S. T. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000004783 · Cited by 217
Kollef, M. H., Chastre, J., Clavel, M., Restrepo, M. I., Michiels, B., Kaniga, K., Cirillo, I., Kimko, H., & Redman, R. (2012) · Critical Care · doi:10.1186/cc11862 · Cited by 208
Veiga, R. P., & Paiva, J.-A. (2018) · Critical Care · doi:10.1186/s13054-018-2155-1 · Cited by 203
“In septic shock, blood misdistribution in the microcirculation might decrease antibiotic concentration at the infection site [1].”
BackgroundDe Waele, J. J., Carrette, S., Carlier, M., Stove, V., Boelens, J., Claeys, G., Leroux-Roels, I., Hoste, E., Depuydt, P., Decruyenaere, J., et al. (2014) · Intensive Care Medicine · doi:10.1007/s00134-013-3187-2 · Cited by 195
Sime, F. B., Roberts, M. S., Peake, S. L., Lipman, J., & Roberts, J. A. (2012) · Annals of Intensive Care · doi:10.1186/2110-5820-2-35 · Cited by 184
“, beta-lactams) [15-17], this role has not been subjected to a structured literature review.”
BackgroundChytra, I., Stepan, M., Benes, J., Pelnar, P., Zidkova, A., Bergerova, T., Pradl, R., & Kasal, E. (2012) · Critical Care · doi:10.1186/cc11405 · Cited by 174
“The use of continuous administration of blactams was studied in some trials [13-22], but strong evidence of clinical efficacy of this alternative is lacking.”
BackgroundAbdul-Aziz, M. H., Lipman, J., Akova, M., Bassetti, M., De Waele, J. J., Dimopoulos, G., Dulhunty, J., Kaukonen, K.-M., Koulenti, D., Martin, C., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv288 · Cited by 168
Management of sepsis and septic shock in the emergency department
Gavelli, F., Castello, L. M., & Avanzi, G. C. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02735-7 · Cited by 161
“, β-lactams, aminoglycosides, glycopeptides) [83].”
Ex Vivo Perfusion Treatment of Infection in Human Donor Lungs
Nakajima, D., Cypel, M., Bonato, R., Machuca, T., İskender, İ., Hashimoto, K., S, V. L., Chen, M., Coutinho, R., Azad, S., et al. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13562 · Cited by 157
Treatment of carbapenem-resistantKlebsiella pneumoniae: the state of the art
Petrosillo, N., Giannella, M., Lewis, R. E., & Viale, P. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.162 · Cited by 178
“The physiological basis for augmented renal clearance is multifactorial, but probably arises from the hyperdynamic [62,66] resuscitation .”
BackgroundInfluentialHobbs, A. L. V., Shea, K. M., Roberts, K. M., & Daley, M. J. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1653 · Cited by 155
Tängdén, T., Martin, V., Felton, T., Nielsen, E. I., Marchand, S., Brüggemann, R. J. M., Bulitta, J. B., Bassetti, M., Theuretzbacher, U., Tsuji, B. T., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4780-6 · Cited by 162
Huttner, A., Harbarth, S., Hope, W. W., Lipman, J., & Roberts, J. A. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv201 · Cited by 184
Therapeutic drug monitoring of anti-infective agents in critically ill patients
Jager, N. G. L., van Hest, R. M., Lipman, J., Taccone, F. S., & Roberts, J. A. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1172209 · Cited by 135
“Large interindividual differences in PK of critically ill patients have been reported for aminoglycosides [37–41], glycopeptides [42–46], β-lactams [47,48], fluoroquinolones [49– 52], colistin [53,54], linezolid [49,55–59], daptomycin [60], fluconazole [61,62], itraconazole [63], posaconazole [64], voriconazole [65–67…”
BackgroundMuller, A. E., Huttner, B. D., & Huttner, A. (2018) · Drugs · doi:10.1007/s40265-018-0880-z · Cited by 138
“Imipenem, meropenem and other carbapenems These drugs are typically eliminated rapidly; patients may have undetectable trough levels [8, 46]”
BackgroundPistolesi, V., Morabito, S., Mario, F. D., Regolisti, G., Cantarelli, C., & Fiaccadori, E. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00583-19 · Cited by 125
Understanding and Managing Sepsis in Patients With Cancer in the Era of Antimicrobial Resistance
Gudiol, C., Albasanz‐Puig, A., Cuervo, G., & Carratalà, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.636547 · Cited by 131
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026
Prescott, H. C., Antonelli, M., Alhazzani, W., Møller, M. H., Alshamsi, F., Azevedo, L. C. P., Belley-Cote, E., De Waele, J., Derde, L., Dionne, J. C., et al. (2026) · Intensive Care Medicine · doi:10.1007/s00134-026-08361-1 · Cited by 141
Case-Control Study of Drug Monitoring of β-Lactams in Obese Critically Ill Patients
Hites, M., Taccone, F. S., Wolff, F., COTTON, F. J., Beumier, M., Backer, D. D., Roisin, S., Lorent, S., Surin, R., Seyler, L., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01083-12 · Cited by 109
Continuous beta-lactam infusion in critically ill patients: the clinical evidence
Abdul-Aziz, M. H., Dulhunty, J. M., Bellomo, R., Lipman, J., & Roberts, J. A. (2012) · Annals of Intensive Care · doi:10.1186/2110-5820-2-37 · Cited by 115
Pettigrew, M. M., Gent, J. F., Kong, Y., Halpin, A. L., Pineles, L. L., Harris, A. D., & Johnson, J. K. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy936 · Cited by 108
“Moreover, the pharmacokinetics of antibiotics may differ in intensive care unit (ICU) patients compared to healthy individuals [11].”
BackgroundDrug absorption, distribution, metabolism and excretion considerations in critically ill adults
Roberts, D. J., & Hall, R. I. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.799137 · Cited by 110
Li, J., Lovern, M., GREEN, M. L., Chiu, J., Zhou, D., Comisar, C. M., Xiong, Y., Hing, J. P., Macpherson, M. P., Wright, J. G., et al. (2018) · Clinical and Translational Science · doi:10.1111/cts.12585 · Cited by 103
“Examining covariates relating to critical illness and septic shock was also important because these can significantly affect the volume of distribution and exposure of many other antimicrobial agents.(43-46)”
BackgroundDelattre, I., Taccone, F., Jacobs, F., Hites, M., Dugernier, T., Spapen, H. D., Laterre, P., Wallemacq, P. E., Françoise Van Bambeke, A., & Tulkens, P. M. (2017) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1338139 · Cited by 112
“Introduction β-lactam antibiotics remain the mainstay of treatment for a variety of bacterial infections, especially when a gram-negative infection is suspected [1].”
BackgroundMensa, J., Barberán, J., Soriano, À., Llinares, P., Marco, F., Cantón, R., Bou, G., del Castillo, J. M. G., Maseda, E., Azanza, et al. (2018) · Europe PMC (PubMed Central) · Cited by 101
Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients
Schleibinger, M., Steinbach, C. L., Töpper, C., Kratzer, A., Liebchen, U., Kees, F., Salzberger, B., & Kees, M. G. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12636 · Cited by 106
Teo, J. Q.-M., Liew, Y., Lee, W., & Kwa, A. L. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.01.027 · Cited by 106
Therapeutic management of peritonitis: a comprehensive guide for intensivists
Montravers, P., Blot, S. I., Dimopoulos, G., Eckmann, C., Eggimann, P., Guirao, X., Paiva, J. A., Sganga, G., & Waele, J. J. D. (2016) · Intensive Care Medicine · doi:10.1007/s00134-016-4307-6 · Cited by 116
Meropenem use and therapeutic drug monitoring in clinical practice: a literature review
Steffens, N. A., Zimmermann, E. S., Nichelle, S. M., & Brucker, N. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13369 · Cited by 98
Richter, D., Frey, O. R., Röhr, A. C., Roberts, J. A., Koeberer, A., Fuchs, T., Papadimas, N., Heinzel‐Gutenbrunner, M., Brenner, T., Lichtenstern, C., et al. (2019) · Infection · doi:10.1007/s15010-019-01352-z · Cited by 106
“CI infusion represents a reasonable approach of customized drug dosing in the ICU as to extend the time that the unbound fraction of PIP remains above the pathogen-specific minimum inhibitory concentration (MIC) (fT>MIC) [6, 7, 13, 14] up to 100% of the dosing interval [10, 12, 15].”
BackgroundSinnollareddy, M., Roberts, M. S., Lipman, J., & Roberts, J. A. (2012) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2012.05715.x · Cited by 105
“In addition, such changes are largely unpredictable, with a great inter- and intrapatient variability over time.(73,87,88) This unpredictability significantly increases the potential for suboptimal concentrations and provides difficult challenges for clinicians in choosing doses that will optimize the dosing to achiev…”
BackgroundTsolaki, V., Mantzarlis, K. D., Mpakalis, A., Malli, E., Tsimpoukas, F., Tsirogianni, A., Papagiannitsis, C., Zygoulis, P., Papadonta, M.-E., Petinaki, E., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02320-19 · Cited by 91
“Critical illness, particularly in patients with severe sepsis and septic shock, results in extreme fluid extravasation into the interstitial space from endothelial damage and capillary leakage (7, 8).”
BackgroundEgi, M., Ogura, H., Yatabe, T., Atagi, K., Inoue, S., Iba, T., Kakihana, Y., Kawasaki, T., Kushimoto, S., Kuroda, Y., et al. (2021) · Acute Medicine & Surgery · doi:10.1002/ams2.659 · Cited by 96
Surviving Sepsis campaign: international guidelines for Management of Sepsis and Septic Shock 2026
Prescott, H. C., Antonelli, M., Alhazzani, W., Møller, M. H., Alshamsi, F., Azevedo, L. C. P., Belley-Cote, E., De Waele, J., Derde, L., Dionne, J. C., et al. (2026) · Critical Care Medicine · doi:10.1097/ccm.0000000000007075 · Cited by 117
Jankovic, S., Aleksic, Z., Milinković, I., & Dimitrijevic, B. (2010) · PubMed · Cited by 84
Optimizing Antimicrobial Drug Dosing in Critically Ill Patients
Póvoa, P. M. S. R., Moniz, P., Gonçalves-Pereira, J., & Coelho, L. (2021) · Microorganisms · doi:10.3390/microorganisms9071401 · Cited by 90
“In this study, ARC (defined as ClCr >130 mL/min) was the main risk factor for underdosing (OR 2.47), but the same is also linked to better baseline organ functional status and a possible better prognosis [212].”
BackgroundInfluentialSelf-citationAntibiotic resistance in cancer patients
Gudiol, C., & Carratalà, J. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.920253 · Cited by 96
Legrand, T., Vodovar, D., Tournier, N., Khoudour, N., & Lesne-Hulin, A. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00176-16 · Cited by 84
β-lactam Therapeutic Drug Management in the PICU*
Cies, J. J., Moore, W. S., Enache, A., & Chopra, A. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002817 · Cited by 95
Kawaguchi, N., Katsube, T., ECHOLS, R. M., & Wajima, T. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01437-20 · Cited by 82
“, 4-fold MIC) were considered a PK/PD index as reported for b-lactams (15).”
BackgroundBaptista, J. P., Neves, M. R., Rodrigues, L., Teixeira, L., Pinho, J. R. R., & Pimentel, J. (2014) · Journal of Nephrology · doi:10.1007/s40620-013-0036-x · Cited by 81
Pea, F., Viale, P., Cojutti, P. G., & Furlanut, M. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01291-12 · Cited by 78
Therapeutic Drug Monitoring of Antibiotics: Defining the Therapeutic Range.
Abdul-Aziz, M. H., Brady, K., Cotta, M. O., & Roberts, J. A. (2022) · PubMed · doi:10.1097/ftd.0000000000000940 · Cited by 48
Zander, J., Maier, B., Suhr, A., Zoller, M., Frey, L., Teupser, D., & Vogeser, M. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-0746 · Cited by 85
Frippiat, F., Musuamba, F. T., Seidel, L., Albert, A., Denooz, R., Charlier, C., Françoise Van Bambeke, A., Wallemacq, P. E., Descy, J., Lambermont, B. C., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku354 · Cited by 75
Ruiz, S., Minville, V., Asehnoune, K., Virtos, M., Georges, B., Fourcade, O., & Conil, J. (2015) · Annals of Intensive Care · doi:10.1186/s13613-015-0090-8 · Cited by 72
Hayashi, Y., Lipman, J., Udy, A. A., Ng, M., McWhinney, B. C., Ungerer, J. P. J., Lust, K. M. C., & Roberts, J. A. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.10.002 · Cited by 81
Tröger, U., Drust, A., Martens‐Lobenhoffer, J., Tanev, I., Braun-Dullaeus, R. C., & Bode‐Böger, S. M. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.05.010 · Cited by 80
Antibiotic dosing during extracorporeal membrane oxygenation: does the system matter?
Abdul-Aziz, M. H., & Roberts, J. A. (2019) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000810 · Cited by 67
“However, the pharmacokinetic estimates in the study are generally consistent with those of critically ill patients without ECMO support [36].”
ResultGatti, M., & Pea, F. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01040-y · Cited by 69
Scharf, C., Paal, M., Schroeder, I., Vogeser, M., Draenert, R., Irlbeck, M., Zöller, M., & Liebchen, U. (2020) · Antibiotics · doi:10.3390/antibiotics9030131 · Cited by 72
“However, the target level in those studies has been defined on the basis of expert opinions and not on the results of patient outcomes [10,14,19].”
BackgroundZhao, H., Gu, J. P., Lyu, J., Liu, D., Wang, Y., Liu, F., Zhu, F., & An, Y. (2017) · Chinese Medical Journal · doi:10.4103/0366-6999.205859 · Cited by 68
Blot, S. I., Lipman, J., Roberts, D. M., & Roberts, J. A. (2014) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.01.015 · Cited by 69
Clinical characteristics of Raoultella ornithinolytica bacteremia
Chun, S., Yun, J. W., Huh, H. J., & Lee, N. Y. (2014) · Infection · doi:10.1007/s15010-014-0696-z · Cited by 65
“However, a systemic review regarding the volume of distribution of beta-lactams showed that in septic patients, the increase in the volume of distribution compared to healthy subjects was larger in carbapenems compared to cephalosporins, although in the case of ceftazidime, the variation of volume distribution did sho…”
BackgroundZander, J., Döbbeler, G., Nagel, D., Maier, B., Scharf, C., Huseyn‐Zada, M., Jung, J., Frey, L., Vogeser, M., & Zöller, M. (2016) · Critical Care · doi:10.1186/s13054-016-1255-z · Cited by 68
“After intermittent administration, PIP concentrations varied substantially among critically ill patients [6–10].”
BackgroundCies, J. J., Moore, W. S., Enache, A., & Chopra, A. (2017) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-22.4.276 · Cited by 65
Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory
Grupper, M., Kuti, J. L., & Nicolau, D. P. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00022-16 · Cited by 72
“, larger volumes of distribution) than in patients who are not critically ill and therefore may lead to underdosing (131).”
BackgroundChandorkar, G., Xiao, A. J., Mouksassi, S., Hershberger, E., & Krishna, G. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.395 · Cited by 63
“Also, patients with other types of infections were not included, and it may be important to identify any additional covariates to extrapolate the results to other infections, such as nosocomial pneumonia.(24,25) However, given that the PK of ceftolozane/ tazobactam is dose-proportional and linear and that CrCL is the…”
BackgroundAntimicrobial Use in Horses Undergoing Colic Surgery
Schaer, B. L. D., Linton, J. K., & Aceto, H. W. (2012) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2012.01024.x · Cited by 62
Fournier, A., Eggimann, P., Pagani, J., Revelly, J., Decosterd, L. A., Marchetti, O., Pannatier, A., Voirol, P., & Que, Y. (2015) · Burns · doi:10.1016/j.burns.2015.01.001 · Cited by 62
Oliva, A., Gizzi, F., Mascellino, M. T., Cipolla, A., D’Abramo, A., D’Agostino, C., Trinchieri, V., Russo, G., Tierno, F., Iannetta, M., et al. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.09.014 · Cited by 58
Heil, E. L., Nicolau, D. P., Farkas, A., Roberts, J. A., & Thom, K. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01008-18 · Cited by 59
Antimicrobial Treatment of Pseudomonas aeruginosa Severe Sepsis
Zakhour, J., Sharara, S. L., Hindy, J.-R., Haddad, S. F., & Kanj, S. S. (2022) · Antibiotics · doi:10.3390/antibiotics11101432 · Cited by 48
Torres, A., Mouton, J. W., & Pea, F. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0418-z · Cited by 59
“A systematic review of pharmacokinetic studies assessing intravenous b-lactam antibiotics in infected patients treated in the ICU reported significant changes in the pharmacokinetics of all six of the agents studied [70].”
BackgroundAssessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients
Gonçalves-Pereira, J., Silva, N. E., Mateus, A., Pinho, C., & Póvoa, P. M. S. R. (2014) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-15-21 · Cited by 87
Self-citationDhaese, S. A. M., Farkas, A., Colin, P. J., Lipman, J., Stove, V. V., Verstraete, A., Roberts, J. A., & Waele, J. J. D. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky434 · Cited by 59
Optimizing the Use of Beta-Lactam Antibiotics in Clinical Practice: A Test of Time
Tilanus, A., & Drusano, G. L. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad305 · Cited by 67
“Subsequently, in 2011, Gonçalves-Pereira and Póvoa [14] published a systematic review of the pharmacokinetics of beta-lactams in which the authors reported significant PK heterogeneity in critically ill patients with an up to 2-fold increase in volume of distribution (Vd) and drug clearance.”
BackgroundInfluentialLipš, M., Šiller, M., Strojil, J., Urbánek, K., Balík, M., & Suchánková, H. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.05.011 · Cited by 53
Arnold, H. M., Hollands, J. M., Skrupky, L. P., Smith, J. R., Juang, P., Hampton, N. B., McCormick, S., Reichley, R. M., Hoban, A. P., Hoffmann, J., et al. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r523 · Cited by 50
“Time from infection onset to death, days, median (IQR) 36 (13-141) 19 (10-45) <0.”
BackgroundAntibiotics in Necrotizing Soft Tissue Infections
Urbina, T., Razazi, K., Ourghanlian, C., Woerther, P., Chosidow, O., Lepeule, R., & de Prost, N. (2021) · Antibiotics · doi:10.3390/antibiotics10091104 · Cited by 57
“For hydrophilic antibiotics, these processes may lead to a large increase in the distribution volume (Vd), an extensively documented phenomenon in critically ill patients [55].”
BackgroundKothekar, A. T., Divatia, J. V., Myatra, S. N., Patil, A., Krishnamurthy, M. N., Maheshwarappa, H. M., Siddiqui, S. S., Gurjar, M., Biswas, S., & Gota, V. (2020) · Annals of Intensive Care · doi:10.1186/s13613-019-0622-8 · Cited by 48
“Pharmacokinetics of meropenem are likely to be altered in patients with severe sepsis compared to healthy volunteers because of infusion of a large volume of fluids and blood products, increased capillary permeability, high cardiac output, augmented renal clearance, or renal hypoperfusion [5].”
BackgroundTse, A., Ling, L., Lee, A. S. Y., & Joynt, G. M. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.07.021 · Cited by 50
Rodvold, K. A., Gotfried, M. H., Chugh, R., Gupta, M., Patel, A. M., Chavan, R. P., Yeole, R. D., Friedland, H. D., & Bhatia, A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00682-18 · Cited by 47
“-lactam agents has been observed in critically ill patients (compared with healthy adult subjects), and alterations in pharmacokinetic parameters and/or intrapulmonary penetration should also be considered in designing dosage regimens of WCK 5222 for the treatment of severe nosocomial pneumonia (11, 27, 28).”
BackgroundAbdelraouf, K., Abuhussain, S. S. A., & Nicolau, D. P. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa373 · Cited by 47
Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients
Dhaese, S. A. M., Roberts, J. A., Carlier, M., Verstraete, A., Stove, V. V., & Waele, J. J. D. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.12.015 · Cited by 48
Can changes in renal function predict variations in β-lactam concentrations in septic patients?
Casu, G. S., Hites, M., Jacobs, F., COTTON, F. J., Wolff, F., Beumier, M., Backer, D. D., Vincent, J., & Taccone, F. S. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.06.021 · Cited by 45
Therapeutic drug monitoring of β-lactam antibiotics in the ICU
Dhaese, S. A. M., Vooren, S. V., Boelens, J., & Waele, J. J. D. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1788387 · Cited by 55
Greppmair, S., Brinkmann, A., Roehr, A. C., Frey, O. R., Hagel, S., Dorn, C., Marsot, A., El‐Haffaf, I., Zöller, M., Saller, T., et al. (2023) · Intensive Care Medicine · doi:10.1007/s00134-023-07154-0 · Cited by 49
“However, critically ill patients commonly exhibit pathophysiological changes, altering the volume of distribution (V d ) and the elimination of antibiotics, making dosing and pharmacodynamic (PD) target attainment challenging [6–8].”
BackgroundReducing medication errors in critical care: a multimodal approach
Latif, A., Kruer, R. M., & Jarrell, A. S. (2014) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s48530 · Cited by 63
“Large volume resuscitations, positive pressure ventilation, surgical procedures, systemic inflammatory response, and changes in protein binding, all common in ICU patients, affect the pharmacokinetics of many drugs.(18) In addition, these patients are usually unable to help facilitate their own care, a problem aggrava…”
Zander, J., Maier, B., Zöller, M., Döbbeler, G., Frey, L., Teupser, D., & Vogeser, M. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-0325 · Cited by 43
The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024
Shime, N., Nakada, T.-A., Yatabe, T., Yamakawa, K., Aoki, Y., Inoue, S., Iba, T., Ogura, H., Kawai, Y., Kawaguchi, A., et al. (2025) · Journal of Intensive Care · doi:10.1186/s40560-025-00776-0 · Cited by 52
Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients
Kees, M. G., Minichmayr, I. K., Moritz, S., Beck, S. M., Wicha, S. G., Kees, F., Kloft, C., & Steinke, T. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.600 · Cited by 44
Antimicrobial Dosing in Acute Renal Replacement
Fissell, W. H. (2012) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2012.10.004 · Cited by 42
“For these reasons, oral administration of pharmacologic agents frequently is not even discussed in reviews of drug dosing in critical illness (12, 13).”
BackgroundRoger, C. (2024) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2023.12.007 · Cited by 57
“63 ] New optimal 𝛽 -lactam loading doses have been suggested (8 g in 3 h for piperacillin, 4 g in 3 h for ceftazidime and cefepime, and 2 g in 0.5 h for meropenem) based on population PK analysis and Monte Carlo simulations (which have gained popularity for the optimization of antibiotic dosing…”
MethodInfluentialCies, J. J., Moore, W. S., Dickerman, M. J., Small, C., Carella, D. M., Chopra, A., & Parker, J. (2014) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1476 · Cited by 41
Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection
Kongthavonsakul, K., Lucksiri, A., Eakanunkul, S., Roongjang, S., Ayuthaya, S. I. N., & Oberdorfer, P. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.04.025 · Cited by 41
Metadata
- Authors
- Gonçalves-Pereira, J., & Póvoa, P.
- Affiliations
- University of Lisbon (PT)
- ORCID
- Póvoa, Pedro
- Venue
- Critical Care
- Published
- 2011-09-13
- Volume
- 15
- Issue
- 5
- Pages
- R206-R206
- ISSN
- 1364-8535 (ISSN-L)
- PMC
- PMC3334750
- OpenAlex
- W2070242840
- Semantic Scholar
- 028a21fcf10a276ab1fc87191ee4ae66b704ce5e
- Cited by
- 408
- References
- 93
- Citations by year
- 2026: 24 · 2025: 25 · 2024: 26 · 2023: 36 · 2022: 32 · 2021: 43 · 2020: 27 · 2019: 22 · 2018: 24 · 2017: 25 · 2016: 27 · 2015: 26 · 2014: 31 · 2013: 17 · 2012: 21
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0/ (tdm)
- creativecommons.org/licenses/by/2.0/ (vor)
- Locations
- Critical Care (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- beta-lactam antibiotics, antibiotic pharmacokinetics, critically ill patients, intensive care unit, volume of distribution, drug clearance, creatinine clearance, half-life, time above MIC, pharmacodynamics, continuous infusion, septic shock, tissue penetration, therapeutic drug monitoring, antibiotic dosing, meropenem, imipenem, piperacillin, cefpirome, cefepime, ceftazidime
- MeSH terms
- Cefepime, Meropenem, Cefpirome, Anti-Bacterial Agents, Ceftazidime, Cephalosporins, Humans, Infections, Piperacillin, Thienamycins, Imipenem, Critical Illness, beta-Lactams
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.